TNFRSF8 and COVID-19: A recent search of ClinicalTrials.gov for the term “aptamer” yielded 53 current and past trials in which aptamers were tested as biosensor, imaging, or therapeutic agents for a variety of pathologies including bladder CA, COVID-19, HIV, age-related macular degeneration, CD30+ lymphoma and solid tumors, and metastatic colorectal and pancreatic cancers.